Definitive collection of precision medicine technology and diagnostic solutions

TruSight™ Oncology 500 (Illumina)

The TruSight Oncology 500 product family enables comprehensive genomic profiling (CGP) from both blood and tissue biopsy samples in house. All three assays in the family are designed to identify key biomarkers in guidelines in clinical trials.


Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
858-202-4500
www.illumina.com

Learn more about this product

REQUEST INFO: TruSight™ Oncology 500 (Illumina)

TruSight Oncology 500

TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling (CGP) of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various tumor types. In addition, it accurately measures key current and emerging immunotherapy biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Oncology 500 High-Throughput

The TruSight Oncology 500 High-Throughput assay is built on the foundation of the TruSight Oncology 500 assay, with added flexibility to batch up to 192 samples per NovaSeq6000 flow cell. Similar to TruSight Oncology 500, it enables CGP from FFPE samples.

Save Time, Money, and Samples Through Assay Consolidation

  • Pan-cancer content aligned with key guidelines and clinical trials
  • DNA + RNA assay targeting 523 genes for assessment of all DNA and RNA variant types, plus MSI and TMB
  • Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay

Achieve Highly Confident Results

  • Hybrid-capture chemistry combined with sophisticated bioinformatics, leading to high analytical specificity and sensitivity
  • Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
  • Based on proven Illumina SBS sequencing technology
  • Integrated 4-5 day workflow, from sample to final genomic report

Unlock Immuno-Oncology

  • Panel contains immuno-oncology biomarkers MSI and TMB
  • Tumor-only workflow for simplicity and efficiency
  • TMB calling performance similar to whole-exome sequencing (WES) panels
  • Large 1.94 Mb panel and sophisticated algorithm for accurate TMB score

TruSight Oncology 500 ctDNA

An NGS-based assay that assesses multiple variant types in 523 cancer-related genes from cell-free DNA (cfDNA). Leveraging the power of the NovaSeq 6000 System for high depth of sequencing, unique molecular identifiers (UMIs), and the ultra-rapid Illumina DRAGEN Server v3, provides high sensitivity and specificity to enable comprehensive genomic profiling from cfDNA.

Enable Comprehensive Genomic Profiling in Plasma

  • Same DNA content as TruSight Oncology 500 for detection of single nucleotide variants (SNVs), indels, CNVs, DNA fusions, TMB, and MSI

Achieve Rapid, Accurate Variant Detection

  • Highly sophisticated variant calling algorithm powered and accelerated by DRAGEN

Achieve Confidence in Results

  • Hybrid-capture chemistry, UMIs and high depth of coverage, and sophisticated error correction improve variant calling and reduce artifacts

Leverage the Power of the NovaSeq 6000 System

  • Enable cfDNA analysis with the required depth of sequencing for low-level variant detection in plasma

Posters & Papers

TruSight™ Oncology 500 (Illumina)

Scroll Up